Review Article

Neoadjuvant chemotherapy for locally advanced cervical cancer

Takashi Iwata, Azumi Miyauchi, Yukako Suga, Hiroshi Nishio, Masaru Nakamura, Akiko Ohno, Nobumaru Hirao, Tohru Morisada, Kyoko Tanaka, Hiroki Ueyama, Hidemichi Watari, Daisuke Aoki


Neoadjuvant chemotherapy followed by surgery (NCS) has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy (NAC) used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Many randomized controlled trials (RCTs) have examined the long-term prognosis of NCS compared to primary surgery, but the utility of NCS remains uncertain. The advent of concurrent chemoradiotherapy (CCRT) has markedly improved the outcome of radiotherapy (RT), and CCRT is now used as a standard method in many cases of advanced bulky cervical cancer. NCS gives a better treatment outcome than radiation therapy alone, but it is important to verify that NCS gives a similar or better outcome compared to CCRT.